UBS analyst Brennan Hawken raised the firm’s price target on Goldman Sachs (GS) to $640 from $610 and keeps a Neutral rating on the shares. The

Goldman Sachs and UBS have emerged as the leading mergers and acquisitions (M&A) financial advisers in South America for 2024, in terms of deal value and volume, respectively, according to the latest league table from GlobalData, a data and analytics firm.

UBS analyst Thomas Wadewitz revised the price target on JetBlue Airways (NASDAQ:JBLU) shares, reducing it to $5.00 from the previous target of $5.50. Despite the adjustment, the firm continues to recommend a Sell rating for the airline's stock.

The Goldman Sachs Group (NYSE:GS – Free Report) had its target price increased by UBS Group from $610.00 to $640.00 in a report issued on Tuesday morning,Benzinga reports.UBS Group currently has ...

UBS Chief Executive Sergio Ermotti on Tuesday said it was currently premature for the Swiss bank to consider acquisitions as it continues to focus on the integration of Credit Suisse, which it bought in 2023.

Indian Finance Minister Nirmala Sitharaman will present the national budget on Feb. 1, in what would be the coalition government's first full-year budget after assuming power in June. The budget comes against the backdrop of a growth slowdown in the world's fifth-largest economy,

Interactive Brokers Group (NASDAQ:IBKR – Get Free Report) had its target price boosted by stock analysts at UBS Group from $225.00 to $265.00 in a note issued to investors on Monday,Benzinga reports.

India and the U.S. are plugging a hole in the market for steel-making coal caused by declining demand in China which has in turn opened opportunities for investors.

Goldman Sachs Group Inc (GS) stock saw a decline, ending the day at $636.9 which represents a decrease of $-2.60 or -0.41% from the prior close of $639.5. The stock opened at $630 and touched a low of $628.

It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share price rises for companies including Telix Pharmaceuticals, Clarity Pharmaceuticals and earlier-stage PYC Therapeutics.

In recent trading, TJX Companies Inc (TJX) stock price has shown some volatility, fluctuating 2.79% over the last five trades and 1.10% over the past 30 trades. This represents a notable shift from earlier in the year.

Stocks headed toward all-time highs as oil fell after President Donald Trump urged OPEC to lower crude prices and said he will push for interest-rate cuts.